During the past 3 years, the average EPS without NRIGrowth Rate was -51.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -36.00% per year.
During the past 6 years, Greenwich LifeSciences's highest 3-Year average EPS without NRI Growth Rate was -28.70% per year. The lowest was -51.10% per year. And the median was -35.40% per year.
Greenwich LifeSciences Earnings per Share (Diluted) Historical Data
The historical data trend for Greenwich LifeSciences's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Greenwich LifeSciences Earnings per Share (Diluted) Chart
Competitive Comparison of Greenwich LifeSciences's Earnings per Share (Diluted)
For the Biotechnology subindustry, Greenwich LifeSciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenwich LifeSciences's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Greenwich LifeSciences's PE Ratio falls into.
Greenwich LifeSciences Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Greenwich LifeSciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.72
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Greenwich LifeSciences (NAS:GLSI) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Greenwich LifeSciences Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of Greenwich LifeSciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Greenwich LifeSciences (Greenwich LifeSciences) Business Description
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLSI has been successfully added to your 